Clinical trials: Organ Transplant Recipients
Organ Transplant, Immunosuppression
Safety and Immunogenicity of 7-Valent Pneumococcal Conjugate Vaccine in Children Receiving Solid Organ Transplants
We plan to study whether the 7-valent pneumococcal conjugate vaccine (Prevnar™) is safe and effective in protecting children who have had a solid organ transplantation and healthy children from pneumococcal infections.
- Trial name
- NCT00213265
- Testing
- 7-valent pneumococcal conjugate vaccine, Pneumococcal 7-valent Conjugate Vaccine
- Where
- Canada
- Volunteers
- 81 people
- Sponsor
- The Hospital for Sick Children
Actinic Keratosis
Fractional Laser-assisted Daylight Photodynamic Therapy Versus Daylight Photodynamic for Treatment of Actinic Keratoses
Organ transplant recipients (OTR) have an increased risk of non-melanoma skin cancer, in particular squamous cell carcinoma (SCC), often developing in areas of field cancerization, areas with multiple precancerous actinic…
- Trial name
- NCT01898936
- Testing
- Pretreatment with CO2 laser before photodynamic therapy, Only photodynamic therapy
- Where
- Norway
- Volunteers
- 12 people
- Sponsor
- Oslo University Hospital
Heart Transplantation, Kidney Transplantation
A Study to Compare How the Body Absorbs and Processes Two Different Formulations of the Anti-rejection Medication Tacrolimus (Advagraf® or Prograf®) in Children Receiving an Organ Transplant, and How Safe and Effective They Are Over a Longer Period of Time
The purpose of this study is to compare how the body absorbs and processes two different formulations of the anti-rejection medication tacrolimus (Advagraf® or Prograf®) in children receiving an organ transplant, and how safe and…
- Conditions
- Heart Transplantation, Kidney Transplantation, Liver Transplantation
- Trial name
- NCT01614665
- Testing
- Tacrolimus, Tacrolimus prolonged release
- Where
- 10 sites in Czechia, France and 3 more
- Volunteers
- 44 people
- Sponsor
- Astellas Pharma Europe Ltd.
Human Papilloma Virus, Hiv
Study of Safety, Tolerability and Immunogenicity of Gardasil®9 in Immunocompromised Patients
Patients with immunodeficiencies are at increased risk of developing persistent HPV infection and as such HPV-related disease (genital warts and cancer).
- Conditions
- Human Papilloma Virus, Hiv, Organ Transplants
- Trial name
- NCT03525210
- Testing
- 9-valent HPV vaccine
- Where
- Belgium
- Volunteers
- 271 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Zoster; Herpes
Zoster Vaccine to Enhance Protection Against Zoster in Solid-organ Transplantation
Shingles is caused by the same virus that causes chickenpox. After someone has chickenpox, the virus stays in the body and can become active again later in life. This is called shingles.
- Trial name
- ZEST (NCT07443709)
- Testing
- Booster dose of the recombinant zoster vaccine (RZV, Shingrix®)
- Where
- Switzerland
- Volunteers
- 75 people
- Sponsor
- Oriol Manuel
Influenza Vaccine
Intradermal Versus Intramuscular Trivalent Influenza Vaccine in Adult Solid Organ Transplant Recipients
Influenza virus is an important cause of morbidity in the transplant population and can lead to viral and bacterial pneumonia and contribute to the development of rejection.
- Trial name
- NCT01180699
- Testing
- Influenza vaccine: Vaxigrip or Fluviral and Intanza
- Where
- Canada
- Volunteers
- 229 people
- Sponsor
- University of Alberta
Infection in Solid Organ Transplant Recipients
Individualization of Ganciclovir and Valganciclovir Doses Using Bayesian Prediction in Renal Transplant Patients.
The objective of the present study is to optimize intravenous ganciclovir(GCV) and oral valganciclovir (VGCV)doses, advised by the drug exposure, indicated by the area under the concentration time curve (AUC), in renal transplant…
- Trial name
- NCT01446445
- Testing
- Ganciclovir/ Valganciclovir according to SPC, Ganciclovir/ Valganciclovir according to PK model
- Where
- Spain
- Volunteers
- 60 people
- Sponsor
- Nuria Lloberas
Microbial Colonization
Gut Microbiome Analysis in Organ Transplant Recipient
The microbiome acts as an antigen and can induce signaling through receptors like TLRs and NODs. Microbial metabolites can directly act on gut cells or reach other organs systemically.
- Trial name
- NCT06405958
- Testing
- gut microbiome
- Volunteers
- 200 people
- Sponsor
- Asan Medical Center
Kidney Transplantation
A Safety and Efficacy Study of FCR001 Cell Therapy in Previously Transplanted Living Donor Kidney Recipients
An open-label study to assess the safety, tolerability, and efficacy of FCR001 cell therapy in adult recipients 3-12 months after kidney transplantation from a living donor.
- Trial name
- FREEDOM-2 (NCT01649388)
- Testing
- FCR001
- Where
- 3 sites in United States
- Sponsor
- Talaris Therapeutics Inc.
Cytomegalovirus Infections
Ganciclovir Resistant/Refractory Cytomegalovirus Infection in SOT Recipients and HSCT Patients
The ReCySOHT study is a multicenter, retrospective, observational case-control study on the risk factors for developing a ganciclovir-resistant/refractory (GCV-RR) cytomegalovirus infection in patients receiving solid organ…
- Trial name
- ReCySOHT (NCT05234723)
- Where
- 23 sites in United States, Belgium and 7 more
- Volunteers
- 100 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Cytomegalovirus (CMV)
A Study of Maribavir in Japanese People With Cytomegalovirus (CMV) Infection
The main aim of the study is to check if maribavir can treat Japanese people with Cytomegalovirus (CMV) infection, and to check side effect from the study treatment and how much maribavir participants can take without getting…
- Trial name
- NCT05137717
- Testing
- Maribavir
- Where
- 20 sites in Japan
- Volunteers
- 41 people
- Sponsor
- Takeda
Cancer, Hematopoietic System--Cancer
Evaluating Immune Response to COVID-19 Vaccines in Patients With Cancer, Transplant or Cellular Therapy Recipients
This study is being done because the investigators would like to learn more about how well the COVID-19 vaccine works in participants with cancer or those who have received a transplant or cellular therapy.
- Conditions
- Cancer, Hematopoietic System--Cancer, Transplant-Related Cancer, Solid Tumor Malignancy
- Trial name
- NCT05164016
- Where
- 3 sites in United States
- Volunteers
- 21 people
- Sponsor
- St. Jude Children's Research Hospital
Kidney Transplant, Liver Transplant
A Cohort Study of Operationally Tolerant Allograft Recipients
Antirejection medicines, also known as immunosuppressive drugs, are prescribed to organ transplant recipients to prevent their bodies from rejecting the new organ.
- Trial name
- ALLTOL (NCT02743793)
- Testing
- Blood Draw
- Where
- 5 sites in United States
- Volunteers
- 41 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Cytomegalovirus, Organ Transplant
Strategic Help With Immunoglobulin to Enhance Protect Against Late Disease (CMV)
This study is being done to find out if administering CytoGam® after the end of standardly prescribed preventive antiviral treatment can help transplant recipients with a high risk for developing late CMV disease after a liver…
- Conditions
- Cytomegalovirus, Organ Transplant, Kidney Transplant; Complications, Liver Transplant Complications
- Trial name
- SHIELD (NCT06958796)
- Testing
- Cytomegalovirus Immune Globulin Intravenous (Human) monthly for three months
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- Camille N. Kotton, MD
Infection in Solid Organ Transplant Recipients
Valganciclovir Dosing in Pediatric Solid Organ Transplant Recipients
Valganciclovir is extensively used for cytomegalovirus (CMV) infection treatment and prophylaxis after solid organ transplantation (SOT). VGC dosing is problematic in children.
- Trial name
- NCT02503982
- Testing
- prophylactic Valganciclovir
- Where
- Israel
- Volunteers
- 13 people
- Sponsor
- Rabin Medical Center
Cutaneous Squamous Cell Carcinoma, Skin Cancer
Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy
This is study is to evaluate the safety and efficacy of cosibelimab in special populations with advanced cutaneous squamous cell carcinoma (CSCC).
- Trial name
- NCT07426484
- Testing
- Cosibelimab, Prednisone, Sirolimus
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- Dana-Farber Cancer Institute
Interstitial Fibrosis, Kidney Transplant; Complications
Fingolimod for the Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney Transplantation
This is a randomized, double-blind, placebo-controlled trial in de novo kidney transplant patients to determine if the addition of fingolimod (brand name Gilenya®, candidate name- FTY720) on the background of standard…
- Conditions
- Interstitial Fibrosis, Kidney Transplant; Complications, Kidney Transplant Rejection, Kidney Transplant Failure and Rejection
- Trial name
- NCT05285878
- Testing
- Fingolimod
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- The Methodist Hospital Research Institute
Malignant Diseases, Non-malignant Diseases
CD34+ Cell Enriched and T Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Mismatched Related Donors or Borderline Organ Function
The purpose of this protocol is to provide access to the CliniMACS® System to hematopoietic cell transplant (HSCT) patients who do not have a matched related donor.
- Trial name
- NCT02162511
- Testing
- CliniMACS CD34+ cell enrichment and T-cell depletion
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Rajni Agarwal
Renal Transplantation
Efficacy and Safety of FTY720 in de Novo Adult Renal Transplant Recipients
This study will evaluate the safety and efficacy of FTY720 combined with cyclosporine and corticosteroids in patients receiving a kidney transplant.
- Trial name
- NCT00239798
- Testing
- FTY720
- Volunteers
- 255 people
- Sponsor
- Novartis Pharmaceuticals
Solid Organ Transplant
iParent2Parent Program for Parents of Pediatric Solid Organ Transplant Recipients
The iParent2Parent (iP2P) program is a new, innovative virtual mentorship program that will connect parents one-to-one with other parents of pediatric solid organ transplant (SOT) recipients who are trained to offer vital peer…
- Trial name
- NCT05968807
- Testing
- iParent2Parent Program
- Where
- Canada
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- The Hospital for Sick Children